Sonoma Pharmaceuticals, Inc.
SNOAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeSonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States,. At a $5.3M market cap, Sonoma Pharmaceuticals, Inc. ranks as a micro-cap company within healthcare. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel.
Market Cap
$5.3M
Beta
1.30
P/E (TTM)
—
P/E (Fwd)
-1.98
EPS (TTM)
$-1.22
EPS (Fwd)
$-0.56
ROE
-42.5%
ROA
-5.4%
Cash
$5.3M
Total Debt
$739,000
Free CF
-$1.5M
52W Change
-71.2%
Annual Financials
Cash vs Debt
Where SNOA stands vs its 150-day and 200-day moving averages
As of the September 17, 2026 close, SNOA finished 24.54% below its 150-day moving average ($1.63) and 40.87% below its 200-day moving average ($2.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SNOA overbought or oversold?
At the September 17, 2026 close, SNOA's RSI(14) was 20.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Sonoma Pharmaceuticals, Inc. holds $5.3M in cash against $739K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$1.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -42.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $13.3M (2023) to $19.5M (2026), reflecting a 47% increase over the period.
With cash comfortably exceeding debt, SNOA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SNOA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.